Combined detection of CEA and CA125 for the diagnosis for lung cancer: A meta-analysis

Abstract

This study aimed to systematically evaluate the value of combined detection of serum CEA and CA125 concentrations for the diagnosis of lung cancer.Related studies regarding the diagnosis of lung cancer were searched in PubMed, Embase, CNKI, and Wanfang using a computer. The number of patients who were true-positive, false-positive, false-negative, and true-negative were extracted from each study. Meta-analysis was performed using the Meta-Disc l.4, RevMan 5.3. Seven studies involving 2,216 cases were finally included. Regarding the diagnosis of lung cancer, the sensitivity, specificity, and diagnostic odds ratio of combined CEA and CA125 detection were higher than those of CEA detection alone. The area under the curve (AUC) of combined detection was 0.90, whereas the independently detected AUC was 0.73. Combined CEA and CA125 detection has higher diagnostic efficiency for lung cancer than CEA detection alone. The significance of combined serum CEA and CA125 detection in lung cancer is confirmed.

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)

“…For patients with chemotherapy as first-line treatment and EGFR-TKIs as second-line treatment. 8 Patients may have been treated with radiation previously, but the radiation area must be less than 25% of the bone marrow area 15 and radiation therapy must end at least four weeks before being enrolled into the group. 9 Main organs are functioning normally (ie, no blood transfusion or blood products within 14 days, no correction with granulocyte-colony stimulating factor and other hematopoietic stimulators): i Blood routine test must be: a Hemoglobin ≥90 g/L b Absolute neutrophil count ≥1.5 × 10 9 /L c Platelets ≥80 × 10 9 /L or higher ii Blood biochemical tests must be:…”

“…7 Patients with hypertension who do not drop to the normal range after antihypertensive medication (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg). 8 Long-term open wounds/fractures. 9 >level II or poorly controlled cardiovascular disease.…”

“…As such, we will use imaging to determine the sum of the diameters of all measured target lesions throughout the experiment, and this will be used as a reference point. Screening criteria for enrolling patients will include RECIST tumor staging criteria, screening patients with tumor diameters and relative increases of 0%–20% after previous EGFR‐TKI monotherapy, and increased CEA levels after previous EGFR‐TKI monotherapy …”

“…Screening criteria for enrolling patients will include REC-IST tumor staging criteria, screening patients with tumor diameters and relative increases of 0%-20% after previous EGFR-TKI monotherapy, and increased CEA levels after previous EGFR-TKI monotherapy. 8 Previous studies have shown that EGFR-TKI combined with an antiangiogenic drug (bevacizumab) is effective in the treatment of advanced NSCLC, and can improve patient survival. [9][10][11][12] The clinical study of bevacizumab combined with erlotinib in EGFR-TKI resistance has also made breakthroughs.…”

An Electrochemical Immunosensor for Sensitive Detection of the Tumor Marker Carcinoembryonic Antigen (CEA) Based on Three-Dimensional Porous Nanoplatinum/Graphene

“…Carcinoembryonic antigen (CEA), an important broad-spectrum tumor biomarker, is used as an efficient prognostic indicator in the early clinical diagnosis and disease prevention of pancreatic cancer [1,2], colorectal cancer [3,4], breast cancer [5,6], lung cancer [7,8], and gastric cancer [9][10][11]. The sensitive detection of low levels of CEA in serum is of great clinical significance in assessing tumor status and therapeutic efficiency, as well as in the early clinical diagnosis of tumor.…”